Karachi: GlaxoSmithKline Pakistan Limited has released its financial results for the nine months ending September 30, 2026, showing a notable increase in revenue alongside rising costs. The company reported these findings on October 29, 2026.

For the quarter ending September 30, 2026, GlaxoSmithKline Pakistan recorded a revenue from contracts with customers of Rs. 16,594,106,000, up from Rs. 14,188,008,000 in the same quarter of the previous year. This represents a very large or significant move in quarterly revenue. Over the nine-month period, the revenue reached Rs. 48.11 billion, compared to Rs. 44.49 billion during the same period in 2025.

The cost of sales for the quarter increased to Rs. 10,109,944,000 from the previous year's Rs. 8,974,557,000. Consequently, the gross profit for the quarter stood at Rs. 6,484,162,000, rising from Rs. 5,213,451,000, reflecting a big move in gross profit.

The company also faced higher selling, marketing, and distribution expenses, which amounted to Rs. 1,524,402,000 for the quarter, up from Rs. 1,305,978,000 the previous year. Administrative expenses saw a minor reduction, with Rs. 521,656,000 recorded against Rs. 527,513,000 in the same quarter last year. Other operating expenses increased to Rs. 359,670,000 from Rs. 288,520,000.

According to information available from the Pakistan Stock Exchange (PSX), other income for the quarter decreased to Rs. 82,154,000 from Rs. 157,432,000 last year. This resulted in an operating profit of Rs. 4,160,588,000, up from Rs. 3,248,872,000, showcasing a big move in operating profit.

The financial charges reflected a reversal, with a cost of Rs. 60,013,000 contrasted with an income of Rs. 42,927,000 in the previous year. Profit before levies and income tax increased to Rs. 4,100,575,000 from Rs. 3,291,799,000.

After accounting for income tax, which rose to Rs. 1,490,112,000 from Rs. 1,254,514,000, the profit after taxation for the quarter was reported at Rs. 2,610,463,000, up from Rs. 2,037,285,000, indicating a big move in profit after taxation.

Earnings per share for the quarter increased to Rs. 8.20 from Rs. 6.40, while for the nine-month period, it rose to Rs. 22.58 from Rs. 19.57.

The designated market category for GlaxoSmithKline Pakistan is the pharmaceutical sector, which remains a key area of focus for stakeholders monitoring the company's financial performance.